Parexel CEO sells $2.4M in stock

- Last updated on GMT

Parexel CEO sells $2.4M in stock
Parexel CEO Josef Von Rickenbach unloaded 50,000 shares of stock last Friday. 

The stock was worth $2.485M, according to SEC documents​. Von Rickenbach still owns about $30M in stock, according to news reports​.

The sell-off comes as Parexel recently exceeded expectations​ with its second quarter results.

Analysts at Barclays raised their price target on Parexel shares from $48.00 to $52.00 in a research note from last week, while analysts at ISI Group upgraded shares of the company’s stock from a “buy​” rating to a “strong-buy​” rating in a research note to investors on Wednesday, January 22nd.

And analysts at Thomson Reuters/Verus downgraded shares of Parexel. One research analyst has rated the stock with a sell rating, seven have given it a hold rating, five have offered a buy rating and two have said the stock deserves a strong buy rating, according to reports. 

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers